Lipid formulations of amphotericin B
Edward Jones, PharmD
Coordinator, investigational drug research, Department of Pharmacy, Methodist Hospitals of Memphis, TN
Morton Goldman, PharmD
Pharmaceutical care clinical manager, Department of Pharmacy, Cleveland Clinic
Address: Edward Jones, PharmD, Department of Pharmacy, Methodist Hospitals of Memphis, 1265 Union Avenue, Memphis, TN 38104-3499
Amphotericin B has long been the mainstay in the treatment of systemic fungal infections, but its nephrotoxicity limits the dosage that can be used. New lipid-based forms may allow higher dosing with less nephrotoxicity. Unfortunately, these new forms are substantially more expensive, and data from randomized clinical trials of their relative efficacy are as yet limited.